GlassScriptPhysician profile
Penny R Brooks
NPI 1669016259
$4,969.37
in general payments reported to CMS, 2019-2025
38 companies · $1,560 in 2025
The $1,560 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,190 · 2022: $1,238 · 2023: $886 · 2024: $95.62 · 2025: $1,560.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,447 · Education: $94.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,446.64 |
| Education | $94.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $870.94 | 2021-2023 | |
| Regeneron Healthcare Solutions, INC. | $483.20 | 2024-2025 | Dupixent |
| Glaxosmithkline, LLC. | $460.06 | 2021-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $454.61 | 2021-2023 | Wegovy |
| Astrazeneca Pharmaceuticals LP | $412.88 | 2021-2025 | Airsupra, Tezspire, Breztri |
| Novartis Pharmaceuticals Corporation | $289.26 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $245.66 | 2021-2023 | Rexulti |
| Csl Behring | $162.98 | 2023-2025 | Andembry, Kcentra |
| Lilly USA, LLC | $151.83 | 2021-2025 | Mounjaro, Ebglyss |
| Amarin Pharma, INC. | $151.06 | 2021-2022 | |
| Ars Pharmaceuticals Operations, INC. | $105.36 | 2025 | Neffy |
| Janssen Pharmaceuticals, INC | $105.02 | 2021-2024 | Xarelto |
| Genzyme Corporation | $103.79 | 2025 | |
| Amgen INC. | $102.32 | 2021-2025 | Tezspire |
| Sanofi-Aventis U.S. LLC | $95.00 | 2022 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Penny Brooks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.